Neurooncology: current findings and challenges for the future

Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathologica. 2007;114:97–109 Cairncross G, Wang M, Shaw E. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;20, 31(3):337–43 van den Bent MJ,BAA van, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;20, 31(3):344–50 Wick W, Platten M, Meisner C, et al. NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer SocietyNOA 08. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–15 Malmström A, Grønberg BH, Marosi C, et al. Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26 Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, Pfister SM. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12(12):818–34 Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A,European Organisation for Research and Treatment of Cancer Brain Tumour Group, EORTC Radiotherapy Group, National Cancer Institute of Canada Clinical Trials Group. Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol. 2005;6(12):937–44